Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
99 hedge funds and large institutions have $111M invested in Paratek Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 9 closing their positions.
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
108% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $708K
88% more capital invested
Capital invested by funds: $58.9M → $111M (+$51.9M)
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
16% more funds holding
Funds holding: 85 → 99 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.9M |
| 2 |
Renaissance Technologies
New York
|
+$2.09M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.03M |
| 4 |
BlackRock
New York
|
+$1.57M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
ICM Asset Management
Spokane,
Washington
|
-$1.31M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.07M |
| 3 |
APCM
Arbiter Partners Capital Management
New York
|
-$608K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$478K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$464K |
PRTK Hedge Fund Activity: Q2 2020 in Review
99 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2020, worth a combined $111M — up 88% from $58.9M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PRTK positions and 9 closed out — a net gain of 14 holders — while 35 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.9M. The largest seller was ICM Asset Management, cutting an estimated $1.31M.
- 99 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2020, up from 85 in Q1 2020.
- Funds reported $111M of Paratek Pharmaceuticals, Inc. stock for Q2 2020, up 88% quarter-over-quarter.
- 23 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2020 and 9 closed out, a net change of +14 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2020 was Morgan Stanley, an estimated $2.9M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2020 was ICM Asset Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2020.